The study was designed to evaluate the effectiveness of the maximum dose of mucolytic solution used before upper endoscopy on the visibility of the gastric mucosa
Residual gastric content containing mucus, bubbles, bile and food particles may limit visibility of gastric mucosa and therefore diagnostic yield of upper endoscopy, especially in cases of early neoplastic lesions. Data on benefit of peroral mucolytic solution administered before upper endoscopy are limited.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Enrollment
120
Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
Administration of water before upper endoscopy
Digestive Diseases Center
Ostrava, Czechia
RECRUITINGVisibility score" evaluated by blinded performing endoscopist
Visibility score" (0-25 points) counted as the sum of visibility score in the esophagus (0-5), fundus (0-5), corpus (0-5) and atrum (0-5) of the stomach and in the duodenum (0-5).
Time frame: through study completion, an average of 5 months
Visibility score" evaluated by two blinded endoscopists using 10 endoscopic images captured during endoscopy
"Visibility score" (0-25 points) counted as the sum of visibility score in the esophagus (0-5), fundus (0-5), corpus (0-5) and atrum (0-5) of the stomach and in the duodenum (0-5).
Time frame: through study completion, an average of 5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.